Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately ...

Moving Tagrisso into the adjuvant setting in early lung cancer, adding to its use as ... Roche has approval for its PD-L1 inhibitor Tecentriq (atezolizumab) after surgery and platinum-based ...

In lung cancer, the PD-L1 inhibitor is already approved ... (NCI), is also looking at Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) as a treatment for limited-stage SCLC, with results due ...

in combination with Tecentriq® (atezolizumab) as maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC). In addition, the S Genprex, Inc. ("Genprex" or the ...

and he reflects on whether tiragolumab is more suited for chemotherapy-naive non–small cell lung cancer than for ES-SCLC, based on the phase 2 CITYSCAPE trial results. Joshua K. Sabari, MD, discusses ...

AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.

Feb. 12, 2025 — Researchers have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous ... Feb. 6, 2025 ...

In the continuing evolution of personalized medicine, a new study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Lung cancer starts in your lungs and can spread to other parts of your body. There are more than 20 kinds of lung cancer. Some other conditions can have similar warning signs to lung cancer.